Allergenic Products Advisory Committee; Cancellation of Meeting, 17583 [2020-06513]

Download as PDF 17583 Federal Register / Vol. 85, No. 61 / Monday, March 30, 2020 / Notices ANNUAL BURDEN ESTIMATES Total/annual number of respondents Instrument Survey of NSCAW Adopted Youth, Young Adults, and Adults ....................... Survey of NSCAW Adoptive Parents .............................................................. Estimated Total Annual Burden Hours: 571 Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Authority: Child Abuse Prevention and Treatment and Adoption Reform Act of 1978. Mary B. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2020–06491 Filed 3–27–20; 8:45 am] BILLING CODE 4184–25–P 588 554 meeting was announced in the Federal Register on February 24, 2020. FOR FURTHER INFORMATION CONTACT: Kathleen Hayes, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6307, Silver Spring, MD 20993–0002, 301– 796–7864, kathleen.hayes@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the Federal Register of February 24, 2020, 85 FR 10451. Dated: March 24, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020–06513 Filed 3–27–20; 8:45 am] Allergenic Products Advisory Committee; Cancellation of Meeting AGENCY: HHS. ACTION: Notice. The meeting of the Allergenic Products Advisory Committee scheduled for May 15, 2020, is canceled. The Allergenic Products Advisory Committee meeting scheduled for May 15, 2020, to discuss and make recommendations on the safety and efficacy of Peanut (Arachis hypogaea) Allergen Extract manufactured by DBV Technologies, S.A, has been canceled to allow time for the FDA to review outstanding issues. The Agency intends to continue evaluating the product and will schedule an Advisory Committee meeting in the future, as needed. The lotter on DSKBCFDHB2PROD with NOTICES VerDate Sep<11>2014 18:05 Mar 27, 2020 Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by April 29, 2020. SUMMARY: SUMMARY: Jkt 250001 294 277 395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0680. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@ fda.hhs.gov. In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. SUPPLEMENTARY INFORMATION: Tracking Network for PETNet, LivestockNet, and SampleNet The Center for Veterinary Medicine and the Partnership for Food Protection developed a web-based tracking network (the tracking network) to allow Federal, State, and Territorial regulatory and public health Agencies to share safety information about animal food. Information is submitted to the tracking network by regulatory and public health Agency employees with membership rights. The efficient exchange of safety information is necessary because it improves early identification and evaluation of a risk associated with an animal food product. We use the information to assist regulatory Agencies to quickly identify and evaluate a risk and take whatever action is necessary to mitigate or eliminate exposure to the risk. Earlier identification and communication with respect to emerging safety information may also mitigate the potential adverse economic impact for the impacted parties associated with such safety issues. The tracking network was developed under the requirements set forth under section 1002(b) of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (Pub. L. 110–085). Section 1002(b) of the FDAAA required FDA, in relevant part, to establish a pet food early warning alert system. AGENCY: Food and Drug Administration, .5 .5 DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tracking Network for PETNet, LivestockNet, and SampleNet [Docket No. FDA–2020–N–0008] Annual burden hours OMB Control Number 0910–0680— Extension [Docket No. FDA–2016–N–0736] Food and Drug Administration 1 1 Average burden hours per response BILLING CODE 4164–01–P Food and Drug Administration DEPARTMENT OF HEALTH AND HUMAN SERVICES Number of responses per respondent To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202– ADDRESSES: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\30MRN1.SGM 30MRN1

Agencies

[Federal Register Volume 85, Number 61 (Monday, March 30, 2020)]
[Notices]
[Page 17583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06513]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0008]


Allergenic Products Advisory Committee; Cancellation of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Allergenic Products Advisory Committee 
scheduled for May 15, 2020, is canceled. The Allergenic Products 
Advisory Committee meeting scheduled for May 15, 2020, to discuss and 
make recommendations on the safety and efficacy of Peanut (Arachis 
hypogaea) Allergen Extract manufactured by DBV Technologies, S.A, has 
been canceled to allow time for the FDA to review outstanding issues. 
The Agency intends to continue evaluating the product and will schedule 
an Advisory Committee meeting in the future, as needed. The meeting was 
announced in the Federal Register on February 24, 2020.

FOR FURTHER INFORMATION CONTACT: Kathleen Hayes, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 6307, Silver Spring, MD 20993-0002, 301-
796-7864, [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), and follow the prompts to the desired center or product area. 
Please call the Information Line for up-to-date information on this 
meeting, which was announced in the Federal Register of February 24, 
2020, 85 FR 10451.

    Dated: March 24, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-06513 Filed 3-27-20; 8:45 am]
 BILLING CODE 4164-01-P